Wegovy (Semaglutide) for Weight Loss: Eligibility, Efficacy, and Critical Considerations
Wegovy® (semaglutide 2.4 mg weekly subcutaneous injection) is a GLP-1 receptor agonist approved by the FDA (2021) for chronic weight management. It mimics the incretin hormone GLP-1, acting on hypothalamic appetite centers (ARC, PVN) to reduce hunger, increase satiety, slow gastric emptying, and improve glycemic control. It is the first pharmacotherapy to demonstrate ~15% mean weight loss in trials (STEP program), approaching bariatric surgery territory.
FDA-Labeled Indication Criteria
- Adults (18+) with:
- Obesity: BMI ≥ 30 kg/m² OR
- Overweight + Comorbidity: BMI ≥ 27 kg/m² with ≥1 weight-related condition: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease.
- Adjunct Requirement: Must be used with reduced-calorie diet and increased physical activity.
Note: Also approved for adolescents ≥12 years with BMI ≥95th percentile (obesity).
Efficacy Snapshot (STEP 1 Trial, 68 weeks)
- Mean weight loss: -14.9% (semaglutide) vs. -2.4% (placebo).
- ≥10% loss: 69% vs 12%. ≥15% loss: 50% vs 5%.
- Improvements in cardiometabolic markers (HbA1c, lipids, BP, CRP), physical function, quality of life.
Critical Clinical Considerations
1. Not a Monotherapy "Cure"
Weight regain is the rule upon discontinuation (STEP 4 extension: 2/3 weight regained at 1 year off drug). Semaglutide treats the *biology* of obesity (dysregulated homeostasis); lifestyle treats the *behavior*. Both are lifelong.
2. Side Effect Profile: GI Dominates
- Very Common (≥10%): Nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), abdominal pain (20%), headache, fatigue.
- Mitigation: Slow titration (monthly escalation), small frequent meals, hydration, avoid fatty/spicy foods, OTC antiemetics prn.
- Serious/Rare: Acute pancreatitis (discontinue), gallbladder disease (cholelithiasis, cholecystitis — rapid weight loss risk), acute kidney injury (volume depletion), diabetic retinopathy complications (rapid glucose improvement), suicidal ideation (monitor), thyroid C-cell tumors (rodent signal; contraindicated in MEN2/personal/family hx MTC).
3. The Cost Barrier
List price: ~$1,350/month ($16,200/year). Insurance coverage highly variable: many commercial plans exclude anti-obesity medications (AOMs); Medicare Part D *excludes* AOMs by statute (though CV benefit indication may change this); Medicaid varies by state. Manufacturer savings card (eligibility restrictions). Compounded semaglutide (quality/sterility concerns; FDA warning).
4. Appropriate Patient Selection Concerns
- Prescribing to BMI <27 without comorbidity (cosmetic use).
- Insufficient lifestyle counseling (15-min visit → prescription).
- Overlooking contraindications (pancreatitis hx, MEN2, pregnancy).
- Neglecting muscle mass preservation (protein + resistance training essential).
- Ignoring eating disorder screening (binge eating, anorexia history — semaglutide may mask restriction).
5. Better-Suited Alternatives?
For some: Older, cheaper generics (phentermine-topiramate/Qsymia, bupropion-naltrexone/Contrave, liraglutide 3.0/Saxenda). For BMI ≥35 or ≥30 with severe comorbidity: Bariatric surgery (sleeve, bypass) — more durable, resolves comorbidities, cost-effective long-term.
Shared Decision-Making Checklist
- Confirm BMI/comorbidity criteria.
- Screen for contraindications, eating disorders, thyroid cancer risk.
- Discuss realistic expectations: gradual loss, plateau, lifelong therapy likely.
- Review insurance/out-of-pocket cost; explore alternatives if prohibitive.
- Co-create nutrition (high protein, fiber) + exercise (resistance 2x/wk) plan.
- Schedule close follow-up: q4 wks titration, then q3 mo maintenance.
Wegovy is a powerful tool in the obesity armamentarium. Its value is maximized only within a comprehensive, longitudinal, multidisciplinary obesity care model—not as a standalone prescription.
Neuro-Linguistic Programming (NLP) - Related Articles
- Homographs: Words Spelled Alike with Different Meanings
- How to Search for Exact Phrases on Google, Bing, DuckDuckGo & Yahoo
- Safe Texting Practices: Avoid Common Pitfalls & Stay Present
- ICD-10-CM Code J7060: Benign Neoplasm of the Bladder
- Modifier -47: Anesthesia by Surgeon – Correction and Proper Usage
- Dermographism: Understanding Skin Writing & Causes
- Spotting COVID-19 Misinformation: A Critical Thinking Guide to Reliable Health Information
